乌斯特基努马
医学
炎症性肠病
促炎细胞因子
克罗恩病
白细胞介素23
病因学
炎症性肠病
不利影响
疾病
免疫学
重症监护医学
白细胞介素17
肿瘤坏死因子α
英夫利昔单抗
炎症
内科学
作者
Weilin Zhang,Guoqiang Zhong,Xiaopeng Ren,Mingsong Li
标识
DOI:10.3389/fimmu.2024.1322054
摘要
Inflammatory bowel disease (IBD) is a chronic, recurrent gastrointestinal disorder with elusive etiology. Interleukin-12 (IL-12) and IL-23 have emerged as key proinflammatory mediators/cytokines in IBD pathogenesis. Ustekinumab (UST), targeting IL-12 and IL-23, has demonstrated promising efficacy and safety in the treatment of IBD. Recently, UST has become increasingly favored as a potential first-line treatment option. This review delineates UST’s mechanism of action, its clinical applications in IBD, including the response rates, strategies for dose optimization for case of partial or lost response, and potential adverse events. This review aims to offer a comprehensive understanding of UST’s role as a therapeutic option in IBD management.
科研通智能强力驱动
Strongly Powered by AbleSci AI